Clinical and Translational Science Collaborative of Cleveland
克利夫兰临床与转化科学合作组织
基本信息
- 批准号:9978966
- 负责人:
- 金额:$ 672.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-15 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseBasic ScienceBiotechnologyCitiesClinicClinicalClinical InvestigatorClinical ResearchClinical SciencesClinical TrialsCollaborationsCommon ColdCommunitiesCountryDisadvantagedEnsureEnvironmentFacultyFoundationsFundingGenetic DiseasesGoalsGovernment AgenciesGrantHealthHealth BenefitHealth systemHealthcareHospitalsHumanIncubatedIndividualInfant MortalityInformaticsInstitutionKnowledgeLaboratoriesLeadershipLife ExpectancyLocationLongevityMalignant NeoplasmsMedical centerMethodsModelingMovementNational Research Service AwardsNeighborhoodsNeurodegenerative DisordersPatientsPersonal SatisfactionPopulationPositioning AttributePreparationProcessProgram DevelopmentRecommendationResearchResearch MethodologyResearch SupportResearch TrainingResourcesScienceSiteSolidSystemTNFSF15 geneTestingTimeTrainingTraining SupportTranslational ResearchTranslationsUnderserved PopulationUnited States Department of Veterans AffairsUnited States National Institutes of HealthUniversitiesUniversity HospitalsVisionbasecareer developmentcatalystclinical research sitecollaborative environmentdesignflexibilityhealth disparityimprovedinner cityinnovationmembermulti-site trialnamed groupnext generationnovel therapeuticsoperationprogramsprototyperesearch clinical testingresearch facilitystatisticssuburbsuccesstranslational scientist
项目摘要
Clinical and translational (C/T) research is essential to bring the discoveries of biomedical science to benefit the
health and well-being of our nation. The Clinical and Translational Science Collaborative (CTSC) of Cleveland,
a collaborative among Case Western Reserve University (CWRU) and its affiliated hospital systems, the
Cleveland Clinic (CC), MetroHealth (MH), University Hospitals (UH), and the Louis Stokes Veterans
Administration Medical Center (VA), aspires to be a catalyst for high quality C/T research both locally and
nationally. The CTSC operates as a fully integrated cooperative, collaborative, and confluent research
environment that supports all aspects of clinical and translational science, enabling full access by university
faculty at all partner institutions to all CTSC-associated potential collaborators and research resources. It has
positioned itself to assume leadership in disseminating best practices and promoting multi-site clinical research.
It now seeks funding to support the development of program support required to advance the goals set forth by
the 2013 recommendations for the CTSA Program by the IOM (now NAM). The CTSC of Cleveland has created
a solid foundation on which to build from, to utilize the power of this collaborative to ensure rigorous and
innovative training of the C/T/ workforce, to accelerate the translation of discoveries to patients, to improve the
health of Cleveland, and to provide scalable models for other locations throughout the nation. To realize its
vision, the CTSC of Cleveland proposes to engage all C/T science stakeholders, the workforce, patients and
community members to collaborate locally, regionally, and nationally, to 1) advance human health, 2) develop
and cultivate the current and next generation C/T research workforce, with special focus on preparation for team
science and increasing the diversity of the workforce, 3) promote integration of our translational processes from
discovery through clinical trials, of our community throughout the research enterprise, and of special and
underserved populations into C/T research across the lifespan, 4) increase the quality and efficiency of C/T
research, particularly multi-site trials, through innovative methods and processes and strong collaboration among
CTSC Hubs, and 5) provide innovative informatics to support the training and research environment both within
the CTSC and nationally. The CTSC has designed an Administrative Core, six C/T research components:
Informatics, Community and Collaboration, Translational Endeavors, Research Methods, Hub Research
Capacity, and Network Capacity; and two formal C/T training cores: Institutional Career Development Core
(KL2), and the NRSA Training Core (TL1) to accomplish its goals. Commitment to collaboration and innovation
in C/T research remain top priorities as the CTSC implements its aims and builds the new iteration of the Clinical
and Translational Science Collaborative of Cleveland.
临床和转化(C/T)研究是必不可少的,使生物医学科学的发现,以造福于
我们国家的健康和福祉。克利夫兰的临床和转化科学合作组织(CTSC),
凯斯西储大学(CWRU)及其附属医院系统之间的合作,
克利夫兰诊所(CC),大都会健康(MH),大学医院(UH)和路易斯斯托克斯退伍军人
管理医学中心(VA),渴望成为本地和本地高质量C/T研究的催化剂,
全国范围内。CTSC作为一个完全集成的合作,协作和融合的研究
支持临床和转化科学的各个方面的环境,使大学能够完全访问
教师在所有合作机构的所有CTSC相关的潜在合作者和研究资源。它有
在传播最佳实践和促进多中心临床研究方面发挥领导作用。
它现在寻求资金,以支持发展所需的方案支助,以推进
2013年,IOM(现在的NAM)对CTSA计划提出了建议。克利夫兰的CTSC创建了
一个坚实的基础上建立,利用这种合作的力量,以确保严格和
C/T/劳动力的创新培训,以加速将发现转化为患者,以改善
克利夫兰的健康,并为全国其他地区提供可扩展的模型。实现其
克利夫兰的CTSC建议让所有C/T科学利益相关者、劳动力、患者和
社区成员在地方、区域和国家各级开展合作,以1)促进人类健康,2)发展
培养当前和下一代C/T研究队伍,特别注重团队准备
科学和增加劳动力的多样性,3)促进我们的翻译过程的整合,
通过临床试验发现,我们的社区在整个研究企业,和特殊的,
在整个生命周期中,将服务不足的人群纳入C/T研究,4)提高C/T的质量和效率
研究,特别是多地点试验,通过创新的方法和流程以及
CTSC中心,以及5)提供创新的信息学,以支持培训和研究环境,
CTSC和国家。CTSC设计了一个行政核心,包括六个C/T研究部分:
信息学,社区与协作,翻译努力,研究方法,枢纽研究
能力和网络能力;以及两个正式的C/T培训核心:机构职业发展核心
(KL2)和NRSA培训核心(TL 1)来实现其目标。致力于合作和创新
随着CTSC实现其目标并建立新的临床迭代,C/T研究仍然是首要任务。
和克利夫兰的转化科学合作组织
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL W. KONSTAN其他文献
MICHAEL W. KONSTAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL W. KONSTAN', 18)}}的其他基金
Clinical and Translational Science Collaborative of Cleveland
克利夫兰临床与转化科学合作组织
- 批准号:
9093875 - 财政年份:2007
- 资助金额:
$ 672.2万 - 项目类别:
Clinical and Translational Science Collaborative of Cleveland
克利夫兰临床与转化科学合作组织
- 批准号:
9093876 - 财政年份:2007
- 资助金额:
$ 672.2万 - 项目类别:
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS
PTC124 作为无义突变介导的囊性纤维化的口服治疗药物
- 批准号:
7378077 - 财政年份:2006
- 资助金额:
$ 672.2万 - 项目类别:
BIIL284BS IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS
BIIL284BS 在成人和儿童囊性纤维化患者中的应用
- 批准号:
7202776 - 财政年份:2005
- 资助金额:
$ 672.2万 - 项目类别:
ORAL THERACLEC-TOTAL IN CF PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY
胰腺外分泌功能不全的 CF 患者口服 THERACLEC-TOTAL
- 批准号:
7202793 - 财政年份:2005
- 资助金额:
$ 672.2万 - 项目类别:
TOBRAMYCIN FOR INHALATION (TOBI) IN YOUNG CHILDREN WITH CYSTIC FIBROSIS
患有囊性纤维化的幼儿吸入用妥布霉素 (Tobi)
- 批准号:
7202765 - 财政年份:2005
- 资助金额:
$ 672.2万 - 项目类别:
BIIL284BS in adult and pediatric cystic fibrosis patients
成人和儿童囊性纤维化患者中的 BIIL284BS
- 批准号:
6974994 - 财政年份:2004
- 资助金额:
$ 672.2万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 672.2万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 672.2万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 672.2万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 672.2万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 672.2万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 672.2万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 672.2万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 672.2万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 672.2万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 672.2万 - 项目类别: